NOVEON MAGNETICS COMPLETES $215 MILLION SERIES C TO EXPAND U.S. RARE EARTH MAGNET MANUFACTURING CAPACITY

NOVEON MAGNETICS COMPLETES $215 MILLION SERIES C TO EXPAND U.S. RARE EARTH MAGNET MANUFACTURING CAPACITY

Financing Round Led by One Investment Management Supports Expansion of Domestic Rare Earth Magnet Production and Facilitates Secondary Share Sale SAN MARCOS, Texas, Jan. 19, 2026 /PRNewswire/ -- Noveon Magnetics, Inc. (Noveon), a leading U.S....

Standard Chartered completes first ICC-Swift API Standards digital bank guarantee transaction through Komgo

Standard Chartered completes first ICC-Swift API Standards digital bank guarantee transaction through Komgo

SINGAPORE, Jan. 15, 2026 /PRNewswire/ -- Standard Chartered has successfully completed its industry standard API-based bank guarantee transaction for a global energy company via Komgo's Konsole, a leading multi-bank trade finance platform. The...

ACEN completes transition to 100% renewable energy

ACEN completes transition to 100% renewable energy

MANILA, Philippines, Dec. 29, 2025 /PRNewswire/ -- ACEN has reached a defining milestone in its transformation journey, having achieved 100% renewable energy generation across its portfolio earlier this year. The milestone underscores a strategic...

Allink Biotherapeutics Completes $47M Extension Rounds of Series A to Accelerate Clinical Programs and Novel Platforms Development

Allink Biotherapeutics Completes $47M Extension Rounds of Series A to Accelerate Clinical Programs and Novel Platforms Development

The company secured $47 million through extension rounds of Series A led by Legend Capital and Meituan Long-Z Investment with strong backing from both new investors and existing supporters Proceeds to advance two differentiated and highly...

DMX-200 ACTION3 PHASE 3 TRIAL COMPLETES RECRUITMENT

DMX-200 ACTION3 PHASE 3 TRIAL COMPLETES RECRUITMENT

Recruitment successfully completed in Dimerix' ACTION3 Phase 3 clinical trial[1], which has recruited and dosed its target 286th adult patient The ACTION3 Phase 3 trial explores the efficacy and safety of DMX-200 in FSGS patients when dosed in...

Exyte completes Pharmaplan integration: A-to-Z execution in GMP facilities

Exyte completes Pharmaplan integration: A-to-Z execution in GMP facilities

Pharmaplan fully integrated into Exyte, unifying biopharma engineering capabilities under one European organization. Integrated setup drives strong client demand and a record order-intake level in 2025. End-to-end EPC/EPCM delivery from feasibility...

Kinetics Successfully Completes $400 Million Bond Issuance, Strengthening Its Position as a Transparent and Recognized Capital Markets Participant

Kinetics Successfully Completes $400 Million Bond Issuance, Strengthening Its Position as a Transparent and Recognized Capital Markets Participant

LONDON, Nov. 6, 2025 /PRNewswire/ -- Kinetics, a Karpowership initiative, has announced the successful completion of a $400 million 4-year senior secured bond issuance, marking an important milestone in its financial strategy and long-term growth....

Samsung Biologics completes spin-off to strengthen its focus as a pure-play CDMO

Samsung Biologics completes spin-off to strengthen its focus as a pure-play CDMO

Spin-off finalized within five months following board resolution Proposal approved in shareholders' meeting with 99.9% support Company to reaffirm its identity as a pure-play CDMO INCHEON, South Korea, Nov. 3, 2025 /PRNewswire/ -- Samsung Biologics...

Novo Tellus completes its transformative growth partnership with Grand Venture Technology

Novo Tellus completes its transformative growth partnership with Grand Venture Technology

Grand Venture Technology embarks on the next chapter of global growth as Aalberts completes the privatisation of the company SINGAPORE, Oct. 31, 2025 /PRNewswire/ -- Novo Tellus, a leading private equity fund focused on building industrial and...

BioDlink Completes First International Shipment of Bevacizumab to Colombia

BioDlink Completes First International Shipment of Bevacizumab to Colombia

Bevacizumab is a targeted therapy used to treat lung and colorectal cancers, both among the top three cancers ranked by death in Colombia[1]. This inaugural shipment—dispatched around two months after Colombia's marketing approval—demonstrates the...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • menu
    menu